ProMIS Neurosciences Inc. has declared the identification of a premier vaccine contender, PMN400.

AC Immune SA to Reclaim Global Ownership of Two Therapeutic Antibodies Post-Partnership with Genentech and Roche.

Ionis reveals encouraging preliminary outcomes from the third phase of the OASIS-HAE trial, examining the experimental compound donidalorsen in individuals with genetic angioedema.

In the CheckMate -8HW study, the combination of Opdivo and Yervoy reduced the likelihood of disease advancement or fatality in patients with MSI-H/dMMR metastatic colorectal cancer by 79% when compared to chemotherapy.

BALVERSA® gains complete sanction from the U.S. FDA to cure bladder cancer in advanced or metastatic stages with specific genetic changes.

Merck Sharp & Dohme (MSD) and Harpoon Therapeutics announced a deal for MSD to purchase Harpoon at $23/share, totaling around $680 million in equity.

Novartis Lutathera® substantially lessens the risk of gastroenteropancreatic neuroendocrine tumors worsening or mortality by 72%.

Bristol Myers Squibb (BMS) and RayzeBio announced a definitive merger, with BMS acquiring RayzeBio for $62.50/share in a deal valued at about $4.1 billion, netting $3.6 billion after accounting for RayzeBio's $500 million cash.

At the 2024 ASCO GI Cancers Symposium, CARsgen Therapeutics presented study results for "satri-cel" (CT041), a Claudin18.2-targeted CAR-T therapy.

Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for around $14 billion, obtaining their novel schizophrenia treatment, KarXT.

Durvalumab (IMFINZI®) combined with transarterial chemoembolization (TACE) and bevacizumab lowered the chance of liver cancer progression or death by 23%.

At the 2024 ASCO GI Cancers Symposium, Coherus showcased encouraging Phase 2 trial results for Casdozokitug, an innovative IL-27-targeted antibody.